Clinical Trial

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Study acronym: DAWN-303
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Protocol Amendment History 2 changes
notable Trial sites expanded: 215 -> 219 locations 2026-08-07
notable Trial sites reduced: 218 -> 214 locations 2026-07-21
Trial Details
NCT Number NCT07522073
Lead Sponsor Incyte Corporation
Collaborators: Qiagen Manchester Ltd
Conditions Solid Tumors
Enrollment 588 participants
Start Date 2026-04-09
Primary Completion 2028-09-15 (estimated)
Study Completion 2029-03-19 (estimated)
Updated on ClinicalTrials.gov 2026-08-06